Recent multisociety practice guidelines have offered more clarity for clinicians who provide sedation outside the operating roomincluding dentists, endoscopists, and proceduralistswhen treating patients on GLP-1 receptor agonists (GLP-1 RAs) like Semaglutide, Ozempic, or Wegovy.sciencedirect Key Recommendations: Shared Decision-Making: Management should involve the patient and all relevant care teams (procedural, anesthesia, prescribing), considering metabolic needs and individual risk factors
This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution
George Koob, Director of NIHs National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Hypotheses 79 (1), 104112
Semaglutide (Wegovy/Ozempic) activates only GLP-1 and produces roughly 15% weight loss at 68 weeks
Clinical EPP patients on afamelanotide implants do experience increased pigmentation and improved tolerance to sunlight, but they do not typically become deeply bronzed in the way Melanotan II users often do
